- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-1-1-mer
- Ligands
- 1 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 9 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-NAG.2: 6 residues within 4Å:- Chain A: Q.355, T.364, T.365, N.378, S.380
- Ligands: NAG.27
No protein-ligand interaction detected (PLIP)NAG-NAG.3: 5 residues within 4Å:- Chain A: N.288, T.290, H.322, N.324, T.406
No protein-ligand interaction detected (PLIP)NAG-NAG.9: 6 residues within 4Å:- Chain G: Q.355, T.364, T.365, N.378, S.380
- Ligands: NAG.41
No protein-ligand interaction detected (PLIP)NAG-NAG.10: 4 residues within 4Å:- Chain G: N.288, T.290, H.322, N.324
No protein-ligand interaction detected (PLIP)NAG-NAG.12: 6 residues within 4Å:- Chain G: V.135, T.136, N.149, S.151, Y.166, D.313
2 PLIP interactions:2 interactions with chain G- Hydrophobic interactions: G:Y.166
- Hydrogen bonds: G:Y.166
NAG-NAG.15: 4 residues within 4Å:- Chain G: N.160
- Chain K: T.129, Q.131, N.153
No protein-ligand interaction detected (PLIP)NAG-NAG.16: 6 residues within 4Å:- Chain K: Q.355, T.364, T.365, N.378, S.380
- Ligands: NAG.55
No protein-ligand interaction detected (PLIP)NAG-NAG.17: 5 residues within 4Å:- Chain K: N.288, T.290, H.322, N.324, T.406
No protein-ligand interaction detected (PLIP)NAG-NAG.19: 5 residues within 4Å:- Chain K: V.135, T.136, N.149, Y.166, D.313
2 PLIP interactions:2 interactions with chain K- Hydrophobic interactions: K:Y.166
- Hydrogen bonds: K:Y.166
- 4 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN.4: 9 residues within 4Å:- Chain A: S.202, P.205, L.254, N.255, N.369, G.371, V.437, S.438
- Ligands: NAG.30
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN.5: 10 residues within 4Å:- Chain A: V.135, T.136, N.149, Y.166, D.313
- Chain F: M.51, T.54, T.55, G.57, G.58
2 PLIP interactions:1 interactions with chain F, 1 interactions with chain A- Hydrogen bonds: F:T.54, F:T.55, A:Y.166
NAG-NAG-BMA-MAN.11: 10 residues within 4Å:- Chain G: S.202, P.205, V.247, L.254, N.255, N.369, G.371, V.437, S.438
- Ligands: NAG.44
2 PLIP interactions:2 interactions with chain G- Hydrogen bonds: G:S.202, G:S.202
NAG-NAG-BMA-MAN.18: 8 residues within 4Å:- Chain K: E.204, P.205, L.254, N.255, N.369, V.437, S.438
- Ligands: NAG.58
No protein-ligand interaction detected (PLIP)- 6 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-FUC.6: 4 residues within 4Å:- Chain B: N.107, E.110
- Chain C: S.107
- Ligands: NAG.34
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:E.110
NAG-FUC.7: 4 residues within 4Å:- Chain B: N.100, S.102, W.103, I.130
2 PLIP interactions:2 interactions with chain B- Hydrogen bonds: B:N.100, B:S.102, B:S.102
- Hydrophobic interactions: B:I.130
NAG-FUC.13: 4 residues within 4Å:- Chain H: N.107, S.109, E.110
- Chain I: S.107
2 PLIP interactions:2 interactions with chain H- Hydrogen bonds: H:S.109, H:S.109
NAG-FUC.14: 4 residues within 4Å:- Chain H: N.100, S.102, Y.127, I.130
1 PLIP interactions:1 interactions with chain H- Hydrogen bonds: H:S.102
- Hydrophobic interactions: H:Y.127
NAG-FUC.20: 4 residues within 4Å:- Chain L: N.107, S.109, E.110
- Chain M: S.107
No protein-ligand interaction detected (PLIP)NAG-FUC.21: 5 residues within 4Å:- Chain L: N.100, S.102, W.103, Y.127, I.130
1 PLIP interactions:1 interactions with chain L- Hydrogen bonds: L:N.100, L:S.102, L:W.103
- 1 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 42 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.22: 4 residues within 4Å:- Chain A: E.88, N.89
- Chain B: G.16, S.17
Ligand excluded by PLIPNAG.23: 4 residues within 4Å:- Chain A: N.227, T.229, S.267, H.344
Ligand excluded by PLIPNAG.24: 1 residues within 4Å:- Chain A: N.138
Ligand excluded by PLIPNAG.25: 1 residues within 4Å:- Chain A: N.347
Ligand excluded by PLIPNAG.26: 3 residues within 4Å:- Chain A: N.269, T.271, N.272
Ligand excluded by PLIPNAG.27: 4 residues within 4Å:- Chain A: Q.355, S.380, N.384
- Ligands: NAG-NAG.2
Ligand excluded by PLIPNAG.28: 3 residues within 4Å:- Chain A: K.327, N.331, W.387
Ligand excluded by PLIPNAG.29: 6 residues within 4Å:- Chain A: Q.286, N.288, N.324, V.325, S.326, R.435
Ligand excluded by PLIPNAG.30: 4 residues within 4Å:- Chain A: N.255, P.284, N.439
- Ligands: NAG-NAG-BMA-MAN.4
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain A: N.294, I.315, V.433
Ligand excluded by PLIPNAG.32: 5 residues within 4Å:- Chain A: V.175, R.185, N.190, T.191
- Chain K: R.301
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain A: N.134, G.145, K.148
Ligand excluded by PLIPNAG.34: 4 residues within 4Å:- Chain B: N.114, M.115, Q.119
- Ligands: NAG-FUC.6
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain B: E.123, N.126
Ligand excluded by PLIPNAG.36: 3 residues within 4Å:- Chain G: E.88, N.89
- Chain H: S.17
Ligand excluded by PLIPNAG.37: 5 residues within 4Å:- Chain G: N.227, T.229, S.267, I.270, H.344
Ligand excluded by PLIPNAG.38: 1 residues within 4Å:- Chain G: N.138
Ligand excluded by PLIPNAG.39: 1 residues within 4Å:- Chain G: N.347
Ligand excluded by PLIPNAG.40: 3 residues within 4Å:- Chain G: N.269, T.271, N.272
Ligand excluded by PLIPNAG.41: 4 residues within 4Å:- Chain G: Q.355, S.380, N.384
- Ligands: NAG-NAG.9
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain G: K.327, N.331, W.387
Ligand excluded by PLIPNAG.43: 6 residues within 4Å:- Chain G: Q.286, N.288, N.324, V.325, S.326, R.435
Ligand excluded by PLIPNAG.44: 4 residues within 4Å:- Chain G: N.255, P.284, N.439
- Ligands: NAG-NAG-BMA-MAN.11
Ligand excluded by PLIPNAG.45: 3 residues within 4Å:- Chain G: N.294, I.315, V.433
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain A: R.301
- Chain G: R.185, N.190
Ligand excluded by PLIPNAG.47: 2 residues within 4Å:- Chain G: N.134, G.145
Ligand excluded by PLIPNAG.48: 2 residues within 4Å:- Chain H: D.113, N.114
Ligand excluded by PLIPNAG.49: 2 residues within 4Å:- Chain H: E.123, N.126
Ligand excluded by PLIPNAG.50: 3 residues within 4Å:- Chain K: E.88, N.89
- Chain L: S.17
Ligand excluded by PLIPNAG.51: 4 residues within 4Å:- Chain K: N.227, T.229, S.267, H.344
Ligand excluded by PLIPNAG.52: 1 residues within 4Å:- Chain K: N.138
Ligand excluded by PLIPNAG.53: 1 residues within 4Å:- Chain K: N.347
Ligand excluded by PLIPNAG.54: 3 residues within 4Å:- Chain K: N.269, T.271, N.272
Ligand excluded by PLIPNAG.55: 3 residues within 4Å:- Chain K: S.380, N.384
- Ligands: NAG-NAG.16
Ligand excluded by PLIPNAG.56: 1 residues within 4Å:- Chain K: N.331
Ligand excluded by PLIPNAG.57: 6 residues within 4Å:- Chain K: Q.286, N.288, N.324, V.325, S.326, R.435
Ligand excluded by PLIPNAG.58: 4 residues within 4Å:- Chain K: N.255, P.284, N.439
- Ligands: NAG-NAG-BMA-MAN.18
Ligand excluded by PLIPNAG.59: 3 residues within 4Å:- Chain K: N.294, I.315, V.433
Ligand excluded by PLIPNAG.60: 3 residues within 4Å:- Chain G: R.301
- Chain K: R.185, N.190
Ligand excluded by PLIPNAG.61: 3 residues within 4Å:- Chain K: N.134, G.145, K.148
Ligand excluded by PLIPNAG.62: 3 residues within 4Å:- Chain L: S.109, D.113, N.114
Ligand excluded by PLIPNAG.63: 4 residues within 4Å:- Chain L: K.122, E.123, S.125, N.126
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Willis, J.R. et al., Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors. Immunity (2022)
- Release Date
- 2022-09-28
- Peptides
- HIV Envelope ApexGT2 gp120: AGK
HIV Envelope ApexGT2 gp41: BHL
RM20A3 Fab Heavy Chain: CIM
RM20A3 Fab Light Chain: DJN
PCT64.35S Fab Light Chain: E
PCT64.35S Fab Heavy Chain: F - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AG
CK
EB
BH
DL
FC
KI
MM
ID
GJ
NN
JE
LF
H
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-1-1-mer
- Ligands
- 1 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 9 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 4 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 6 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 42 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Willis, J.R. et al., Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors. Immunity (2022)
- Release Date
- 2022-09-28
- Peptides
- HIV Envelope ApexGT2 gp120: AGK
HIV Envelope ApexGT2 gp41: BHL
RM20A3 Fab Heavy Chain: CIM
RM20A3 Fab Light Chain: DJN
PCT64.35S Fab Light Chain: E
PCT64.35S Fab Heavy Chain: F - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AG
CK
EB
BH
DL
FC
KI
MM
ID
GJ
NN
JE
LF
H